Thesis (M. Phil.)--University of Hong Kong, 2006. / Title proper from title frame. Also available in printed format.

Apesar de mais de 20 anos de esforço, o design de uma vacina anti-HIV eficaz ainda constitui um enorme desafio. Neste cenário, novas abordagens imunológicas devem ser consideradas. Monócitos de pares discordantes e de indivíduos sadios não expostos ao HIV foram diferenciados in vitro em células dendríticas (DCs), pulsadas com diferentes antígenos do HIV e co-cultivadas com linfócitos autólogos. A resposta imunológica desenvolvida pelos linfócitos T e o perfil fenotípico e funcional das DCs foram avaliados. Todas as DCs utilizadas no co cultivo apresentavam-se maduras e ativadas. Linfócitos estimulados por DC pulsadas com HIV inativado ou proteína p55Gag apresentaram maior ativação, proliferação e produção de IFN<font face=\"Symbol\">&#947 em comparação a linfócitos estimulados por DCs não pulsadas. Entretanto, as células T do grupo controle apresentaram o mesmo padrão de resposta imunológica, com exceção da produção de IFN<font face=\"Symbol\">&#947. Este modelo vacinal pode representar uma alternativa viável e promissora de vacinação terapêutica contra o HIV. / Despite more than 20 years of effort, the design of an effective HIV-1 vaccine remains an enormous challenge. In this scenario, new immunological approaches must be considered. Monocytes from HIV-serodiscordant couples and non HIV exposed controls were differentiated in vitro into dendritic cells (MoDC), pulsed with different virus antigens and cultured with autologous lymphocytes. The T lymphocyte immunological response and the MoDC phenotype and function were determined. MoDCs were shown to be fully matured and activated in all antigen-pulsing protocols. Lymphocytes stimulated by DC pulsed with inactivated HIV or p55Gag protein showed greater activation, proliferation and IFN<font face=\"Symbol\">&#947 production in comparison to those stimulated by non pulsed MoDC. Nonetheless, T cells from non-exposed controls elicited the same response, except for the IFN<font face=\"Symbol\">&#947 production. This MoDC vaccine model may represent a viable and promising alternative of therapeutic vaccination against HIV.

Apesar de mais de 20 anos de esforço, o design de uma vacina anti-HIV eficaz ainda constitui um enorme desafio. Neste cenário, novas abordagens imunológicas devem ser consideradas. Monócitos de pares discordantes e de indivíduos sadios não expostos ao HIV foram diferenciados in vitro em células dendríticas (DCs), pulsadas com diferentes antígenos do HIV e co-cultivadas com linfócitos autólogos. A resposta imunológica desenvolvida pelos linfócitos T e o perfil fenotípico e funcional das DCs foram avaliados. Todas as DCs utilizadas no co cultivo apresentavam-se maduras e ativadas. Linfócitos estimulados por DC pulsadas com HIV inativado ou proteína p55Gag apresentaram maior ativação, proliferação e produção de IFN<font face=\"Symbol\">&#947 em comparação a linfócitos estimulados por DCs não pulsadas. Entretanto, as células T do grupo controle apresentaram o mesmo padrão de resposta imunológica, com exceção da produção de IFN<font face=\"Symbol\">&#947. Este modelo vacinal pode representar uma alternativa viável e promissora de vacinação terapêutica contra o HIV. / Despite more than 20 years of effort, the design of an effective HIV-1 vaccine remains an enormous challenge. In this scenario, new immunological approaches must be considered. Monocytes from HIV-serodiscordant couples and non HIV exposed controls were differentiated in vitro into dendritic cells (MoDC), pulsed with different virus antigens and cultured with autologous lymphocytes. The T lymphocyte immunological response and the MoDC phenotype and function were determined. MoDCs were shown to be fully matured and activated in all antigen-pulsing protocols. Lymphocytes stimulated by DC pulsed with inactivated HIV or p55Gag protein showed greater activation, proliferation and IFN<font face=\"Symbol\">&#947 production in comparison to those stimulated by non pulsed MoDC. Nonetheless, T cells from non-exposed controls elicited the same response, except for the IFN<font face=\"Symbol\">&#947 production. This MoDC vaccine model may represent a viable and promising alternative of therapeutic vaccination against HIV.

O câncer cervical é o segundo câncer mais comum entre mulheres no mundo. A maioria dos casos (83%) ocorre em países em desenvolvimento, onde são encontrados em estágios relativamente avançados e, conseqüentemente, a sobrevida média é de cerca de 49% após cinco anos. Portanto, uma vacina eficaz contra as infecções pelo HPV pode levar ao controle do câncer do colo do útero. Apesar de prevenir, a vacina profilática não é acessível em função do alto custo, além de não eliminar o vírus em mulheres já infectadas pelo HPV. Assim, propusemos o desenvolvimento de uma vacina terapêutica eficaz utilizando duas abordagens: VLPs (virus-like particles) quiméricas, que poderiam apresentar propriedades profiláticas e terapêuticas, obtidas da fusão das proteína L1 e E7; proteínas quiméricas obtidas a partir da fusão de epítopos das proteínas E6 e E7 do HPV16, com e sem ubiquitina. Após subclonagens, com a obtenção dos vetores pPICHOLI-L1&#916;CE71-50 e pPICHOLI-L1&#916;CE743-77, partiu-se para a indução da expressão das VLPs quiméricas em Pichia pastoris, das quais não foram detectadas expressão protéica. Realizaram-se inúmeras modificações no protocolo de indução. Mesmo após essas alterações não foi detectada nenhuma expressão das fusões L1&#916;CE71-50 ou L1&#916;CE743-77. Como alternativa de uma vacina terapêutica, nos propusemos a expressar em E. coli proteínas sintéticas originadas da fusão entre epítopos das proteínas E6 e E7 do HPV16, com ou sem Ubiquitina, visando aumentar a apresentação de peptídeos via MHC de classe I de modo a estimular a eliminação de células infectadas com HPV16, evitando e regredindo o desenvolvimento dessas células cancerosas. Com a proteína E6E7 solúvel e purificada, realizou-se um ensaio de imunização. Nesse experimento, 20% dos animais imunizados com a proteína E6E7 não apresentaram desenvolvimento de tumor após a inoculação de células TC1. Assim isso nos leva a crer que com o aumento da concentração de proteína e utilização de adjuvantes seria possível aumentar o número de animais resistentes ao desenvolvimento do tumor. Em um segundo experimento de imunização, comparamos as proteínas E6E7 e E6E7Ub, em duas concentrações, 15 e 40 &#181;g, e também com ou sem o adjuvante whole cell pertussis (WCP). Independentemente da concentração e presença ou ausência de WCP, os grupos imunizados com E6E7Ub apresentaram proteção contra o tumor entre 80% e 100% dos camundongos, enquanto os grupos imunizados com E6E7 apresentaram proteção entre 0% e 25%. Esses resultados são promissores, ainda que preliminares, indicando um potencial de uso da proteína E6E7Ub como imunógeno para vacina terapêutica contra o câncer cervical induzido por HPV16 / Cervical cancer is the second most common cancer among women worldwide. Most cases (83%) occur in developing countries, where they are found in relatively advanced stages and, consequently, the median survival is about 49% after five years. Therefore, an effective vaccine against HPV infections can lead to control of cancer of the cervix. Although preventable, the prophylactic HPV vaccine is not accessible to all due to their high cost and in addition the vaccine does not eliminate the HPV in infected women. We have therefore proposed the development of effective therapeutic vaccines using two approaches: chimeric VLPs (virus-like particles), endowed with prophylactic and therapeutic properties, obtained from the fusion protein L1 and E7; chimeric proteins derived from the fusion of epitopes of proteins E6 and E7 of HPV16 with and without ubiquitin. After subcloning, we obtained the vectors pPICHOLI-L1&#916;CE71-50 and L1 pPICHOLI- L1&#916;CE743-77. After transformation of yeast Pichia pastoris with these constructions, the cells were induced, but it was not possible to detect any recombinant protein expression. As an alternative, we proposed the expression of synthetic proteins in E. coli derived from the fusion between epitopes of E6 and E7 proteins of HPV16 with or without Ubiquitin, in order to enhance the presentation of peptides through MHC class I to stimulate the elimination of HPV16-infected cells, preventing and regressing the development of cancer cells. Soluble E6E7 protein was purified and, 20% of the animals immunized with this protein did not develop tumor after inoculation of TC1 cells. In a second immunization experiment we compared the proteins E6E7 and E6E7Ub, in two concentrations, 15 and 40&#181;g, with or without the adjuvant whole cell pertussis (WCP). Regardless of concentration and presence or absence of WCP, all the groups immunized with E6E7Ub showed protection against tumor between 80% and 100%, while the groups immunized with E6E7 showed protection from 0% to 25%. These results are promising and although preliminary, indicate the potential of E6E7Ub protein as an immunogen, for a therapeutic vaccine against cervical cancer induced by HPV16

<p>Human Coronaviruses (HCoVs) are found within the family Coronaviridae (genus, Coronavirus) and are enveloped, single-stranded, positive-sense RNA viruses. Infections of humans by&nbsp / coronaviruses are not normally associated with severe diseases. However, the identification of the coronavirus responsible for the outbreak of severe acute respiratory syndrome (SARS-CoV)&nbsp / showed that highly pathogenic coronaviruses can enter the human population. The SARS-CoV epidemic resulted in 8 422 cases with 916 deaths globally (case fatality rate: 10.9%). In 2004 a&nbsp / group 1 Coronavirus, designated Human Coronavirus NL63 (HCoV-NL63), was isolated from a 7 month old Dutch child suffering from bronchiolitis. In addition, HCoV-NL63 causes disease in&nbsp / children (detected in approximately 10% of respiratory tract infections), the elderly and the immunocompromised. This study was designed to express the full length nucleocapsid (N) proteins of&nbsp / HCoV-NL63 and SARS-CoV for antibody production in an animal model. The NL63-N/pFN2A and SARSN/ pFN2A plasmid constructs were used for this study. The presence of the insert on the Flexi &reg / vector was confirmed by restriction endonuclease digest and sequence verification. The sequenced chromatographs obtained from Inqaba Biotec were consistent with sequences from&nbsp / the NCBI Gen_Bank. Proteins were expressed in a KRX Escherichia coli bacterial system and analysed using 15% SDS-PAGE and Western Blotting. Thereafter, GST-tagged proteins were purified&nbsp / ith an affinity column purification system. Purified fusion proteins were subsequently cleaved with Pro-TEV Plus protease, separated on 15% SDS-PAGE gel and stained with Coomassie&nbsp / Brilliant Blue R250. The viral fusion proteins were subsequently used to immunize Balbc mice in order to produce polyclonal antibodies. A direct ELISA was used to analyze and validate the&nbsp / production of polyclonal antibodies by the individual mice. This is a preliminary study for development of diagnostic tools for the detection of HCoV-NL63 from patient samples collected in the&nbsp / Western Cape.</p>

<p>Human Coronaviruses (HCoVs) are found within the family Coronaviridae (genus, Coronavirus) and are enveloped, single-stranded, positive-sense RNA viruses. Infections of humans by&nbsp / coronaviruses are not normally associated with severe diseases. However, the identification of the coronavirus responsible for the outbreak of severe acute respiratory syndrome (SARS-CoV)&nbsp / showed that highly pathogenic coronaviruses can enter the human population. The SARS-CoV epidemic resulted in 8 422 cases with 916 deaths globally (case fatality rate: 10.9%). In 2004 a&nbsp / group 1 Coronavirus, designated Human Coronavirus NL63 (HCoV-NL63), was isolated from a 7 month old Dutch child suffering from bronchiolitis. In addition, HCoV-NL63 causes disease in&nbsp / children (detected in approximately 10% of respiratory tract infections), the elderly and the immunocompromised. This study was designed to express the full length nucleocapsid (N) proteins of&nbsp / HCoV-NL63 and SARS-CoV for antibody production in an animal model. The NL63-N/pFN2A and SARSN/ pFN2A plasmid constructs were used for this study. The presence of the insert on the Flexi &reg / vector was confirmed by restriction endonuclease digest and sequence verification. The sequenced chromatographs obtained from Inqaba Biotec were consistent with sequences from&nbsp / the NCBI Gen_Bank. Proteins were expressed in a KRX Escherichia coli bacterial system and analysed using 15% SDS-PAGE and Western Blotting. Thereafter, GST-tagged proteins were purified&nbsp / ith an affinity column purification system. Purified fusion proteins were subsequently cleaved with Pro-TEV Plus protease, separated on 15% SDS-PAGE gel and stained with Coomassie&nbsp / Brilliant Blue R250. The viral fusion proteins were subsequently used to immunize Balbc mice in order to produce polyclonal antibodies. A direct ELISA was used to analyze and validate the&nbsp / production of polyclonal antibodies by the individual mice. This is a preliminary study for development of diagnostic tools for the detection of HCoV-NL63 from patient samples collected in the&nbsp / Western Cape.</p>

O câncer cervical é o segundo câncer mais comum entre mulheres no mundo. A maioria dos casos (83%) ocorre em países em desenvolvimento, onde são encontrados em estágios relativamente avançados e, conseqüentemente, a sobrevida média é de cerca de 49% após cinco anos. Portanto, uma vacina eficaz contra as infecções pelo HPV pode levar ao controle do câncer do colo do útero. Apesar de prevenir, a vacina profilática não é acessível em função do alto custo, além de não eliminar o vírus em mulheres já infectadas pelo HPV. Assim, propusemos o desenvolvimento de uma vacina terapêutica eficaz utilizando duas abordagens: VLPs (virus-like particles) quiméricas, que poderiam apresentar propriedades profiláticas e terapêuticas, obtidas da fusão das proteína L1 e E7; proteínas quiméricas obtidas a partir da fusão de epítopos das proteínas E6 e E7 do HPV16, com e sem ubiquitina. Após subclonagens, com a obtenção dos vetores pPICHOLI-L1&#916;CE71-50 e pPICHOLI-L1&#916;CE743-77, partiu-se para a indução da expressão das VLPs quiméricas em Pichia pastoris, das quais não foram detectadas expressão protéica. Realizaram-se inúmeras modificações no protocolo de indução. Mesmo após essas alterações não foi detectada nenhuma expressão das fusões L1&#916;CE71-50 ou L1&#916;CE743-77. Como alternativa de uma vacina terapêutica, nos propusemos a expressar em E. coli proteínas sintéticas originadas da fusão entre epítopos das proteínas E6 e E7 do HPV16, com ou sem Ubiquitina, visando aumentar a apresentação de peptídeos via MHC de classe I de modo a estimular a eliminação de células infectadas com HPV16, evitando e regredindo o desenvolvimento dessas células cancerosas. Com a proteína E6E7 solúvel e purificada, realizou-se um ensaio de imunização. Nesse experimento, 20% dos animais imunizados com a proteína E6E7 não apresentaram desenvolvimento de tumor após a inoculação de células TC1. Assim isso nos leva a crer que com o aumento da concentração de proteína e utilização de adjuvantes seria possível aumentar o número de animais resistentes ao desenvolvimento do tumor. Em um segundo experimento de imunização, comparamos as proteínas E6E7 e E6E7Ub, em duas concentrações, 15 e 40 &#181;g, e também com ou sem o adjuvante whole cell pertussis (WCP). Independentemente da concentração e presença ou ausência de WCP, os grupos imunizados com E6E7Ub apresentaram proteção contra o tumor entre 80% e 100% dos camundongos, enquanto os grupos imunizados com E6E7 apresentaram proteção entre 0% e 25%. Esses resultados são promissores, ainda que preliminares, indicando um potencial de uso da proteína E6E7Ub como imunógeno para vacina terapêutica contra o câncer cervical induzido por HPV16 / Cervical cancer is the second most common cancer among women worldwide. Most cases (83%) occur in developing countries, where they are found in relatively advanced stages and, consequently, the median survival is about 49% after five years. Therefore, an effective vaccine against HPV infections can lead to control of cancer of the cervix. Although preventable, the prophylactic HPV vaccine is not accessible to all due to their high cost and in addition the vaccine does not eliminate the HPV in infected women. We have therefore proposed the development of effective therapeutic vaccines using two approaches: chimeric VLPs (virus-like particles), endowed with prophylactic and therapeutic properties, obtained from the fusion protein L1 and E7; chimeric proteins derived from the fusion of epitopes of proteins E6 and E7 of HPV16 with and without ubiquitin. After subcloning, we obtained the vectors pPICHOLI-L1&#916;CE71-50 and L1 pPICHOLI- L1&#916;CE743-77. After transformation of yeast Pichia pastoris with these constructions, the cells were induced, but it was not possible to detect any recombinant protein expression. As an alternative, we proposed the expression of synthetic proteins in E. coli derived from the fusion between epitopes of E6 and E7 proteins of HPV16 with or without Ubiquitin, in order to enhance the presentation of peptides through MHC class I to stimulate the elimination of HPV16-infected cells, preventing and regressing the development of cancer cells. Soluble E6E7 protein was purified and, 20% of the animals immunized with this protein did not develop tumor after inoculation of TC1 cells. In a second immunization experiment we compared the proteins E6E7 and E6E7Ub, in two concentrations, 15 and 40&#181;g, with or without the adjuvant whole cell pertussis (WCP). Regardless of concentration and presence or absence of WCP, all the groups immunized with E6E7Ub showed protection against tumor between 80% and 100%, while the groups immunized with E6E7 showed protection from 0% to 25%. These results are promising and although preliminary, indicate the potential of E6E7Ub protein as an immunogen, for a therapeutic vaccine against cervical cancer induced by HPV16

Un mini-transposon qui permet une mutagénèse stable et non marquée a été modifié pour permettre l’expression de gènes chez les mycoplasmes. Cet outil a tout d’abord été utilisé pour le développement de mycoplasmes fluorescents. Pour ce faire, les protéines mCherry, mKO2 et mNeonGreen ont été insérées dans le chromosome de deux espèces de mycoplasmes phylogénétiquement distants : Mycoplasma mycoides subsp. mycoides (Mmm) et Mycoplasma bovis (M. bovis). Cette insertion a permis l’observation sans précédent de colonies fluorescentes vertes et rouges chez les deux espèces et ce, sans toxicité apparente. De plus, des niveaux de fluorescence équivalents ont été quantifiés par cytométrie en flux chez les deux espèces, ce qui suggère que l’outil développé peut être largement utilisé chez les mycoplasmes. Ces mycoplasmes fluorescents ont ensuite été utilisés pour effectuer des études d’adhésion, d’invasion et de persistance de ces deux espèces de mycoplasmes avec différents types cellulaires bovins. Ces analyses ont confirmé que M. bovis présente de meilleures capacités d’adhésion et prolifération au support de culture, ainsi qu’aux cellules embryonnaires épithéliales qu’il envahi. Il présente aussi une meilleure résistance à la l’élimination par les macrophages. Néanmoins, Mmm a aussi été détecté à l’intérieur des macrophages après 72 heures d’infection, et ce, même à des MOI faibles et en présence de concentrations bactériostatiques d’antibiotique. Ensuite, le système d’expression a été utilisé pour tester la possibilité d’utiliser les mycoplasmes en tant que vecteurs vaccinaux. Le gène de la protéine H du virus de la peste des petits ruminants, utilisé avec succès dans des vaccins recombinants, a été inséré dans un mycoplasme caprin comme preuve de concept d’un vaccin multivalent. Cependant, malgré la détection d’ARNm spécifique, l’expression de la protéine virale n’a pas été mise en évidence, et ce, malgré le recours à une technique très sensible de détection par spectrométrie de masse. La preuve de concept n’a donc pas pu être réalisée. Pour conclure, les systèmes d’expression de gènes de fluorescences développés dans ces travaux sont bien adaptés aux études d’interaction hôte-pathogène et offrent une multitude de perspectives pour l’analyses fonctionnelle chez les mycoplasmes in vitro et in vivo.. / A mini-transposon affording unmarked, stable mutagenesis in mycoplasmas was modified to allow gene expression. This tool was first used for the development of fluorescence expression for stable and innocuous whole mycoplasma cell labelling. For this purpose, the fluorescent proteins GFP2, mCherry, mKO2 and mNeonGreen were introduced as chromosomal tags in the phylogenetically distant species Mycoplasma mycoides subsp. mycoides (Mmm) and Mycoplasma bovis (M. bovis), resulting in the unprecedented observation of red and green fluorescent mycoplasma colonies in the two species, with no apparent cytotoxicity. Equivalent fluorescence expression levels were quantified by flow cytometry in both species, suggesting that these tools can be broadly applied in mycoplasmas. These fluorescent mycoplasmas were then used to compare the adhesion, invasion and persistence of the two species in different bovine cells. They notably confirmed that M. bovis shows a higher adhesion and proliferation capacity to the inert culture surface and higher adhesion to embryonic lung epithelial cells, which it invades. It also shows an increased resistance to elimination by macrophages. However, fluorescent Mmm were also detected inside the phagocytes 72h post-infection, even at a low MOI. Finally, the expression vector was used to assess the possible use of mycoplasmas as vaccine vectors. For this purpose, we introduced the H gene of the “peste des petits ruminants” virus, already used in effective recombinant vaccines, in a caprine mycoplasma as proof-of-concept of a mycoplasma-based multivalent vaccine. However, despite the detection of specific mRNA, the expression of the viral protein could not be evidenced using a highly a sensitive peptide detection technique by mass spectrometry, so this prove of concept could not be delivered. Still, the fluorescence expression tools developed in this study are suitable for host-pathogen interaction studies and offer innumerable perspectives for the functional analysis of mycoplasmas both in vitro and in vivo.

>Magister Scientiae - MSc / Human Coronaviruses (HCoVs) are found within the family Coronaviridae (genus, Coronavirus) and are enveloped, single-stranded, positive-sense RNA viruses. Infections of humans by coronaviruses are not normally associated with severe diseases. However, the identification of the coronavirus responsible for the outbreak of severe acute respiratory syndrome (SARS-CoV) showed that highly pathogenic coronaviruses can enter the human population. The SARS-CoV epidemic resulted in 8 422 cases with 916 deaths globally (case fatality rate: 10.9%). In 2004 a group 1 Coronavirus, designated Human Coronavirus NL63 (HCoV-NL63), was isolated from a 7 month old Dutch child suffering from bronchiolitis. In addition, HCoV-NL63 causes disease in children (detected in approximately 10% of respiratory tract infections), the elderly and the immunocompromised. This study was designed to express the full length nucleocapsid (N) proteins of HCoV-NL63 and SARS-CoV for antibody production in an animal model. The NL63-N/pFN2A and SARSN/ pFN2A plasmid constructs were used for this study. The presence of the insert on the Flexi ® vector was confirmed by restriction endonuclease digest and sequence verification. The sequenced chromatographs obtained from Inqaba Biotec were consistent with sequences from the NCBI Gen_Bank. Proteins were expressed in a KRX Escherichia coli bacterial system and analysed using 15% SDS-PAGE and Western Blotting. Thereafter, GST-tagged proteins were purified ith an affinity column purification system. Purified fusion proteins were subsequently cleaved with Pro-TEV Plus protease, separated on 15% SDS-PAGE gel and stained with Coomassie Brilliant Blue R250. The viral fusion proteins were subsequently used to immunize Balbc mice in order to produce polyclonal antibodies. A direct ELISA was used to analyze and validate the production of polyclonal antibodies by the individual mice. This is a preliminary study for development of diagnostic tools for the detection of HCoV-NL63 from patient samples collected in the Western Cape. / South Africa

The immune response to an infection is determined by a number of factors, which also affect the generation of memory T cells afterwards. The immune response can also affect the stability of the pre-existing memory populations. The memory developed after an infection can influence the response to subsequent infections with unrelated pathogens. This heterologous immunity may deviate the course of disease and alter the disease outcome. The generation and stability of memory CD8 T cells and the influence of the history of infections on subsequent heterologous infections are studied in this thesis using different viral infection sequences. Previous studies using mice lacking individual immunoproteasome catalytic subunits showed only modest alterations in the CD8 T cell response to lymphocytic choriomeningitis virus (LCMV). In this study, I found that the CD8 T cell response to LCMV was severely impaired in mice lacking all three catalytic subunits of the immunoproteasome, altering the immunodominance hierarchy of the CD8 T cell response and CD8 T cell memory. Adoptive transfer experiments suggested that both inefficient antigen presentation and altered T cell repertoire contribute to the reduction of the CD8 T cell response in the immunoproteasome knockout mice. Immune responses generated during infections can reduce pre-existing memory T cell populations. Memory CD8 T cells have been shown to be reduced by subsequent heterologous infections. In this study, I re-examined the phenomenon using immune mice infected with LCMV, murine cytomegalovirus (MCMV) and vaccinia virus (VACV) in different infection sequences. I confirmed that memory CD8 T cells were reduced by heterologous infections, and showed that LCMV-specific memory CD4 T cells were also reduced by heterologous infections. Reduction of the memory CD8 T cells is thought to be the result of apoptosis of memory CD8 T cells associated with the peak of type I interferon early during infection. I showed that memory CD4 T cells were similarly driven to apoptosis early during infection; however, Foxp3+ CD4+ regulatory T cells were relatively resistant to virus infection-induced apoptosis, and were stably maintained during LCMV infection. The stability of Treg cells during viral infections may explain the relatively low incidence of autoimmunity associated with infections. The history of infections can deviate the course of disease and affect the disease outcome, but this heterologous immunity is not necessarily reciprocal. Previous studies have shown the effects of heterologous immunity during acute infections. In this thesis, I showed that the history of LCMV infection led to higher viral titers during persistent MCMV infection, caused more severe immunopathology at the beginning of infection, and reduced the number of MCMV-specific inflationary memory CD8 T cells after the period of memory inflation. In a different context of infection, the history of LCMV infection can be beneficial. LCMV-immune mice have been shown to have lower viral titers after VACV infection, but VACV-immune mice are not protected during LCMV infection. I found that memory CD8 T cells generated from LCMV and VACV infections were phenotypically different, but the differences could not explain the nonreciprocity of heterologous immunoprotection. By increasing the number of crossreactive VACV A11R198-205-specific memory CD8 T cells, however, I showed that some VACV-immune mice displayed reduced viral titers upon LCMV challenge, suggesting that the low number of potentially cross-reactive CD8 T cells in VACV-immune mice may be part of the reasons for the non-reciprocity of immunoprotection between LCMV and VACV. Further analysis deduced that both number of potentially cross-reactive memory CD8 T cells and the private specificity of memory CD8 T cell repertoire played a part in determining the outcome of heterologous infections.